Niagen Bioscience (NASDAQ:NAGE) vs. Interparfums (NASDAQ:IPAR) Critical Analysis

Interparfums (NASDAQ:IPAR) and Niagen Bioscience (NASDAQ:NAGE) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

55.6% of Interparfums shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 43.6% of Interparfums shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Interparfums and Niagen Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interparfums	$1.49 billion	2.53	$168.39 million	$5.23	22.50
Niagen Bioscience	$129.42 million	1.87	$17.38 million	$0.18	16.92

Interparfums has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Interparfums has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Interparfums and Niagen Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interparfums	2	4	2	1	2.22
Niagen Bioscience	0	1	3	1	3.00

Interparfums presently has a consensus target price of $123.29, suggesting a potential upside of 4.76%. Niagen Bioscience has a consensus target price of $10.33, suggesting a potential upside of 239.35%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Interparfums.

Profitability

This table compares Interparfums and Niagen Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interparfums	11.17%	15.21%	10.85%
Niagen Bioscience	12.39%	17.95%	13.17%

About Interparfums

Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. It operates in two segments, European Based Operations and United States Based Operations. The company offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Moncler, Montblanc, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, Donna Karan, DKNY, Emanual Ungaro, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta, Ungaro, and Roberto Cavalli brands, as well as French Connection, Intimate, and Dunhill, Lacoste names. It sells its products to department stores, perfumeries, specialty stores, duty free shops, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.

About Niagen Bioscience

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.